Important Survey from NVA! June 11, 2013
Help NVA Collect Much-Needed Information on Treatment Effectiveness
First Multi-Site Treatment Registry to Enroll Additional 350 Women in 2012
NVA is committed to continuing its support of the first National Vulvodynia Treatment Outcomes Registry, because due to a lack of research, clinicians and patients have little to no scientific evidence on which to base important medical decisions. The only way that women will ever be informed of the treatment(s) proven effective for their specific vulvodynia subtype – thereby decreasing the time between diagnosis and initiation of effective treatment – is through this type of research! Please help us collect this vital data to help women who are currently suffering as well as those who will come after us.
Over the next 10 months, an additional 350 women age 21 and older will be able to participate in this important study. Registry investigators collect a wealth of neurological, infectious, immunological and genetic data from participants at several time points after initiating treatment – all of which will be correlated to the effectiveness of different vulvodynia therapies. This study will not only lead to the identification of factors that can predict treatment effectiveness, but will help us understand the underlying mechanisms associated with different vulvodynia subtypes. Participation is voluntary, does not include any experimentation and does not change women’s treatment recommendations.
To speak to the Registry’s Research Coordinator Katy Capote about participating at any of the sites, please call 407-303-2721 or send an email to firstname.lastname@example.org.
Medical professionals interested in obtaining Registry flyers to distribute to their patients should also contact Ms. Capote.
To read more about the project, including information on the Registry Investigators, please visit NVA’s web site.
Registry sites are located in:
Little Rock, Arkansas
Los Angeles, California
Fort Lauderdale, Florida (coming soon)
New York City, New York (coming soon)
Pittsburgh, Pennsylvania (coming soon)